Ocumetics Secures Funding for Clinical Trials
Company Announcements

Ocumetics Secures Funding for Clinical Trials

Ocumetics Technology Corp (TSE:OTC) has released an update.

Ocumetics Technology Corp has successfully completed the first part of its private placement, raising CA$2.82 million through the issuance of secured convertible debentures. These funds are earmarked primarily for the company’s inaugural in-human clinical trials and ongoing R&D. The debentures, bearing an 18% annual interest rate, allow holders to convert their debt into common shares at $0.32 each.

For further insights into TSE:OTC stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskOcumetics Unveils Breakthrough Adaptive Intraocular Lens
TipRanks Canadian Auto-Generated NewsdeskOcumetics Unveils New Injector System for Eye Surgery
TipRanks Canadian Auto-Generated NewsdeskOcumetics Kicks Off Landmark Vision Correction Study
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App